STING1 and neoplasm: In this study, we administered 2′3′‐cGAMP on the tumor site and hypothesized that it would mainly activate the STING pathway in non‐malignant cells, particularly immune cells in the tumor tissue, instead of activating the STING pathway inside the tumor cells.